FIELD: Sub-Analysis on Amputation Risk in Diabetics

12 Dec, 10

0

FIELD Sub-Analysis on Amputation Risk in Diabetics

Fenofibrate significantly reduces risk of first amputations by 36% in diabetics: Analysis of FIELD study

Amputations in diabetics substantially impair their quality of life and impose high costs on health care system.

To assess the effects of fenofibrate on amputations in diabetics.

Analysis of Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Type 2 diabetes (N=9795)

Micronized fenofibrate 200 mg (N=4895) vs. placebo (N=4900)

5 years

Incidence of amputations

Fenofibrate significantly reduced the risk of first amputations by 36% as compared to placebo; benefits emerged after just 1.5 years use of fenofibrate (Figure 1). Effects of fenofibrate were independent of the use of ACE inhibitors and angiotensin receptor blockers, glycemic control and dyslipidemia.

Figure 1. Incidence of amputations in both groups

Risk of minor amputations was significantly reduced by 46% in fenofibrate recipients (Figure 2)

Figure 2. Incidence of minor amputations

Risk of multiple amputations was significantly reduced by 37% with fenofibrate therapy (Figure 3)

Figure 3. Incidence of multiple amputations

Findings support the use of fenofibrate, irrespective of the presence of dyslipidemia, for the treatment of patients with type 2 diabetes who are at high risk for amputations
This approach could help to reduce the substantial morbidity, mortality, and economic burden associated with amputation due to diabetes

Lancet 2009;373:1780-88

0